Search Results - "de Oliveira, Mariana Bleker"

Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism by Fernando, Rodrigo Carlini, Mazzotti, Diego Robles, Azevedo, Hatylas, Sandes, Alex Freire, Rizzatti, Edgar Gil, de Oliveira, Mariana Bleker, Alves, Veruska Lia Fook, Eugênio, Angela Isabel Pereira, de Carvalho, Fabrício, Dalboni, Maria Aparecida, Martins, David Correa, Colleoni, Gisele Wally Braga

“…A growing body of evidence suggests a key role of tumor microenvironment, especially for bone marrow mesenchymal stem cells (MSC), in the maintenance and…”
Get full text

Analytical Challenges in Development of Chemoresistance Predictors for Precision Oncology by Bleker de Oliveira, Mariana, Koshkin, Vasilij, Liu, Geoffrey, Krylov, Sergey N

“…Chemoresistance, i.e., tumor insensitivity to chemotherapy, shortens life expectancy of cancer patients. Despite the availability of new treatment options,…”
Get full text

Spheroid-Based Approach to Assess the Tissue Relevance of Analysis of Dispersed-Settled Tissue Cells by Cytometry of the Reaction Rate Constant by Koshkin, Vasilij, Bleker de Oliveira, Mariana, Peng, Chun, Ailles, Laurie E, Liu, Geoffrey, Covens, Allan, Krylov, Sergey N

“…Cytometry of Reaction Rate Constant (CRRC) uses time-lapse fluorescence microscopy to measure a rate constant of a catalytic reaction in individual cells and,…”
Get full text

TP53 Regulated Inhibitor of Apoptosis 1 (TRIAP1) stable silencing increases late apoptosis by upregulation of caspase 9 and APAF1 in RPMI8226 multiple myeloma cell line by Fook-Alves, Veruska L., de Oliveira, Mariana Bleker, Zanatta, Daniela B., Strauss, Bryan E., Colleoni, Gisele W.B.

“…TP53 Regulated Inhibitor of Apoptosis 1 (TRIAP1) modulates apoptotic pathways preventing the formation of the apoptosome complex. Our group previous study…”
Get full text

In Vitro JAK1/2 Inhibition, in Association with Bortezomib and Lenalidomide, Is Comparable with Bortezomib, Lenalidomide and Dexametasone: An Alternative for Multiple Myeloma Patients with JAK2 overexpression? by Bleker de Oliveira, Mariana, Fook Alves, Veruska Lia, Eugenio, Angela Isabel, Carlini Fernando, Rodrigo, Yamamoto, Mihoko, Colleoni, Gisele W.B.

“…Background: Despite the absence of JAK1 and JAK2 mutations in multiple myeloma (MM), high levels of IL-6 constitutively activate the JAK/STAT pathway promoting…”
Get full text

Multiple Myeloma Cancer Stem Cells: Immunophenotypic and Functional Characterization, Gene Expression Profiling and Therapeutic Targets by Bleker de Oliveira, Mariana, Marino Dantonio, Paola, Fook Alves, Veruska Lia, Carlini Fernando, Rodrigo, Teixeira, Daniela, Basso, Alexandre, Yamamoto, Mihoko, Colleoni, Gisele W.B.

“…Background: Despite the increase in patients' survival over the last years, multiple myeloma (MM) remains incurable, being persistence of cancer stem cells…”
Get full text

Heat Shock Protein 70 Inhibitor, Alone or in Combination with Bortezomib, Prevented Plasmacytoma Development in Immunodeficient Mice Transplanted with Myeloma Cell Lines by Bleker de Oliveira, Mariana, Eugenio, Angela Isabel, Fook Alves, Veruska Lia, Zanatta, Daniela, Yamamoto, Mihoko, Strauss, Bryan Eric, Colleoni, Gisele W.B.

“…Introduction: HSP70 has an integrative role in protein degradation due to the interaction with many pathways, such as ubiquitin proteasome (UPS), unfolded…”
Get full text

Proteasome and heat shock protein 70 (HSP70) inhibitors as therapeutic alternative in multiple myeloma by Eugênio, Angela Isabel Pereira, Fook-Alves, Veruska Lia, de Oliveira, Mariana Bleker, Fernando, Rodrigo Carlini, Zanatta, Daniela B, Strauss, Bryan Eric, Silva, Maria Regina Regis, Porcionatto, Marimélia Aparecida, Colleoni, Gisele Wally Braga

“…HSP70 connects multiple signaling pathways that work synergistically to protect tumor cells from death by proteotoxic stress and represents a possible target…”
Get full text

Activation of the Janus kinase/signal transducer and activator of transcription pathway in multiple myeloma is not related to point mutations in kinase and pseudokinase domains of JAK1 by Corbi, Fernanda C., de Oliveira, Mariana Bleker, Morelli, Vania M., Han, Sang W., Renauld, Jean-Christophe, Knoops, Laurent, Colleoni, Gisele W. B.

“…Abstract Considering the recent impact of tyrosine kinase inhibitors in the treatment of myeloproliferative disorders carrying a recurrent JAK2 mutation not…”
Get full text

Multi‑drug‑resistance efflux in cisplatin‑naive and cisplatin‑exposed A2780 ovarian cancer cells responds differently to cell culture dimensionality by Koshkin, Vasilij, De Oliveira, Mariana, Peng, Chun, Ailles, Laurie  , Liu, Geoffrey, Covens, Allan, Krylov, Sergey

“…A primary reason for chemotherapy failure is chemoresistance, which is driven by various mechanisms. Multi-drug resistance (MDR) is one such mechanism that is…”
Get full text